Kolexia
Largillier Remy Oncologie médicale
Largillier Remy
Oncologie médicale
Hp A. Tzanck Mougins Sophia Antipolis
Mougins, France
89 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs du sein Tumeurs de l'ovaire Récidive tumorale locale Carcinome épithélial de l'ovaire Métastase tumorale Anémie Hypersensibilité Tumeurs du pancréas Tumeurs de la prostate

Collaborateurs

Voir plus
Hoch Benjamin
Hoch Benjamin
Hp A. Tzanck Mougins Sophia Antipolis, Mougins, France
Azouza Wakil
Azouza Wakil
Hp A. Tzanck Mougins Sophia Antipolis, Mougins, France
Braccini Antoine
Braccini Antoine
Hp A. Tzanck Mougins Sophia Antipolis, Mougins, France
Naman Herve
Naman Herve
Hp A. Tzanck Mougins Sophia Antipolis, Mougins, France

Industries

Voir plus
AstraZeneca
3 collaboration(s)
Dernière en 2020
VIATRIS MEDICAL
2 collaboration(s)
Dernière en 2022
Servier
2 collaboration(s)
Dernière en 2023
MundiPharma
2 collaboration(s)
Dernière en 2020

Dernières activités

Voir plus
DOMENICA: Randomized Phase III Trial in MMR Deficient Endometrial Cancer Patients Comparing Chemotherapy Alone Versus Dostarlimab in First Line Advanced/Metastatic Setting
Essai Clinique (GSK)   28 février 2024
ATALANTE: A Randomized, Double-blinded, Phase III Study of Atezolizumab Versus Placebo in Patients With Late Relapse of Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer Treated by Platinum-based Chemotherapy and Bevacizumab
Essai Clinique (Roche)   02 janvier 2024
LBA42 Olaparib vs placebo as maintenance therapy after platinum-based chemotherapy in advanced/metastatic endometrial cancer patients: The GINECO randomized phase IIb UTOLA trial
Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023.   01 octobre 2023
Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology   29 août 2023
MITO16MANGO2b: Multicenter Phase III Randomized Study With Second Line Chemotherapy Plus or Minus Bevacizumab in Patients With Platinum Sensitive Epithelial Ovarian Cancer Recurrence After a Bevacizumab/Chemotherapy First Line
Essai Clinique (National Cancer Institute)   23 mars 2023
CHEOPS trial: a GINECO group randomized phase II assessing addition of a non-steroidal aromatase inhibitor to oral vinorelbine in pre-treated metastatic breast cancer patients.
Breast cancer (Tokyo, Japan)   05 janvier 2023
Regorafenib or Tamoxifen for platinum-sensitive recurrent ovarian cancer with rising CA125 and no evidence of clinical or RECIST progression: A GINECO randomized phase II trial (REGOVAR).
Gynecologic oncology   23 octobre 2021
Real-World Experience of Bevacizumab as First-Line Treatment for Ovarian Cancer: The GINECO ENCOURAGE Cohort of 468 French Patients.
Frontiers in pharmacology   20 septembre 2021
739P Efficacy and safety of maintenance olaparib and bevacizumab (bev) in ovarian cancer (OC) patients (pts) aged ≥65 years (y) from the PAOLA-1/ENGOT-ov25 first-line trial
Abstract Book of the ESMO Congress 2021, 16 – 21 September 2021   01 septembre 2021
Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial.
The Lancet. Oncology   18 février 2021